Abstract |
The association between the sparteine/ debrisoquine ( CYP2D6) oxidation polymorphism and the risk of Parkinson's disease was examined in a meta-analysis of case-control studies. The odds ratio was calculated for the risk of Parkinson's disease among poor metabolisers compared with extensive metabolisers. Twenty-one studies were identified of which six were excluded because they were not reported as full papers (n = 3), used incomplete genotype analysis (n = 2) or used Parkinson patients as both control individuals and cases (n = 1). The overall odds ratio was 1.48 (95% confidence interval 1.10-1.99). The odds ratio was 1.05 (95% confidence interval 0.63-1.77) in studies discriminating extensive and poor metabolisers by phenotyping (n = 8) and 1.67 (95% confidence interval 1.11-2.50) in studies using genotyping (n = 7). This difference was caused by a single large study using genotyping. We conclude that there is no convincing evidence of an association between the debrisoquine/ sparteine polymorphism and Parkinson's disease. However, it could prove worthwhile to perform another large study using genotyping.
|
Authors | P M Christensen, P C Gøtzsche, K Brøsen |
Journal | Pharmacogenetics
(Pharmacogenetics)
Vol. 8
Issue 6
Pg. 473-9
(Dec 1998)
ISSN: 0960-314X [Print] England |
PMID | 9918130
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Sparteine
- Cytochrome P-450 CYP2D6
- Debrisoquin
|
Topics |
- Aged
- Case-Control Studies
- Cohort Studies
- Cytochrome P-450 CYP2D6
(genetics, metabolism)
- Debrisoquin
(metabolism)
- Genetic Heterogeneity
- Humans
- Middle Aged
- Odds Ratio
- Oxidation-Reduction
- Parkinson Disease
(enzymology, genetics)
- Polymorphism, Genetic
- Risk Factors
- Sparteine
(metabolism)
|